abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 10일 13시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

Target of atherosclerosis therapy: ACAT and Lp-PLA2 inhibitors

등록일
2006년 8월 30일 20시 07분 29초
접수번호
1279
발표코드
금14A3심 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
금 10시 : 30분
발표형식
심포지엄
발표분야
생명화학 - Enzyme Catalysis and Regulation
저자 및
공동저자
정태숙
한국생명공학연구원 지질대사조절소재연구실,
Atherosclerosis is an inflammatory and sclerosing arterial disease. Inhibition of ACAT2 may reduce plasma cholesterol levels, whereas inhibition of ACAT1 may reduce the cholesterol burden in plaque macrophages. On the basis of this concept, the isotype-specific inhibitor screening systems have been established for the recombinant and cell-based hACAT-1 and -2. Lp-PLA2, an independent marker of coronary heart disease, hydrolyzes the sn-2 fatty acid of oxidatively modified LDL to release oxidized fatty acid and lyso-PC. These two products are highly effective inflammatory mediators capable of attracting monocytes and driving the atherogenic process. We have discovered the ACAT and Lp-PLA2 inhibitors from natural or synthetic compounds. We will discuss the merit and weak point of human ACATs and Lp-PLA2 as drug targets for pharmaceutical interventions against atherosclerosis.

상단으로